{"product_id":"rofaday","title":"Rofaday","description":"\u003ch3 data-start=\"343\" data-end=\"369\"\u003eWhat is Roflumilast?\u003c\/h3\u003e\r\n\u003cp data-start=\"370\" data-end=\"750\"\u003e\u003cstrong data-start=\"370\" data-end=\"385\"\u003eRoflumilast\u003c\/strong\u003e is an oral, selective phosphodiesterase‑4 (PDE4) inhibitor approved for use as a maintenance treatment in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. It works by reducing airway inflammation, thereby improving lung function and decreasing the frequency of COPD exacerbations.\u003c\/p\u003e\r\n\u003cp data-start=\"752\" data-end=\"903\"\u003e\u003cem data-start=\"752\" data-end=\"903\"\u003eReference: U.S. Food and Drug Administration (FDA) Roflumilast Prescribing Information; World Health Organization (WHO) guidelines on COPD management\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"905\" data-end=\"908\"\u003e\r\n\u003ch3 data-start=\"910\" data-end=\"965\"\u003eWhat are the other popular names for Roflumilast?\u003c\/h3\u003e\r\n\u003cp data-start=\"966\" data-end=\"1029\"\u003eRoflumilast is marketed under several brand names, including:\u003c\/p\u003e\r\n\u003cul data-start=\"1030\" data-end=\"1130\"\u003e\r\n\u003cli data-start=\"1030\" data-end=\"1082\"\u003e\n\u003cstrong data-start=\"1032\" data-end=\"1045\"\u003eDaliresp®\u003c\/strong\u003e (widely used in the United States)\u003c\/li\u003e\r\n\u003cli data-start=\"1083\" data-end=\"1130\"\u003e\n\u003cstrong data-start=\"1085\" data-end=\"1096\"\u003eAriflo®\u003c\/strong\u003e (in some international markets)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1132\" data-end=\"1173\"\u003e\u003cem data-start=\"1132\" data-end=\"1173\"\u003eReference: U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1175\" data-end=\"1178\"\u003e\r\n\u003ch3 data-start=\"1180\" data-end=\"1233\"\u003eWhat is the drug classification of Roflumilast?\u003c\/h3\u003e\r\n\u003cp data-start=\"1234\" data-end=\"1443\"\u003eRoflumilast is classified as an \u003cstrong data-start=\"1266\" data-end=\"1299\"\u003eoral selective PDE4 inhibitor\u003c\/strong\u003e. It falls under the therapeutic category of \u003cstrong data-start=\"1344\" data-end=\"1397\"\u003eanti-inflammatory agents for respiratory diseases\u003c\/strong\u003e, specifically used in the management of COPD.\u003c\/p\u003e\r\n\u003cp data-start=\"1445\" data-end=\"1499\"\u003e\u003cem data-start=\"1445\" data-end=\"1499\"\u003eReference: U.S. FDA; World Health Organization (WHO)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1501\" data-end=\"1504\"\u003e\r\n\u003ch3 data-start=\"1506\" data-end=\"1554\"\u003eWhat is the mode of action of Roflumilast?\u003c\/h3\u003e\r\n\u003cp data-start=\"1555\" data-end=\"1751\"\u003eRoflumilast works by inhibiting the enzyme phosphodiesterase‑4 (PDE4) in inflammatory cells. This inhibition increases intracellular cyclic adenosine monophosphate (cAMP) levels, which leads to:\u003c\/p\u003e\r\n\u003cul data-start=\"1752\" data-end=\"1987\"\u003e\r\n\u003cli data-start=\"1752\" data-end=\"1868\"\u003e\n\u003cstrong data-start=\"1754\" data-end=\"1804\"\u003eReduced Release of Pro-inflammatory Mediators:\u003c\/strong\u003e Lowering cytokine production and inflammation in the airways.\u003c\/li\u003e\r\n\u003cli data-start=\"1869\" data-end=\"1987\"\u003e\n\u003cstrong data-start=\"1871\" data-end=\"1892\"\u003eImproved Airflow:\u003c\/strong\u003e By reducing inflammation, it helps alleviate bronchoconstriction and improves lung function.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1989\" data-end=\"2061\"\u003e\u003cem data-start=\"1989\" data-end=\"2061\"\u003eReference: PubMed (e.g., studies on PDE4 inhibition in COPD); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2063\" data-end=\"2066\"\u003e\r\n\u003ch3 data-start=\"2068\" data-end=\"2098\"\u003eHow is Roflumilast used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2099\" data-end=\"2405\"\u003eRoflumilast is used as a \u003cstrong data-start=\"2124\" data-end=\"2149\"\u003emaintenance treatment\u003c\/strong\u003e in patients with severe COPD, particularly in those with chronic bronchitis who are prone to frequent exacerbations. It is intended for long‑term use as part of a comprehensive treatment plan that may also include bronchodilators and other COPD therapies.\u003c\/p\u003e\r\n\u003cp data-start=\"2407\" data-end=\"2492\"\u003e\u003cem data-start=\"2407\" data-end=\"2492\"\u003eReference: American Thoracic Society (ATS) guidelines; U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2494\" data-end=\"2497\"\u003e\r\n\u003ch3 data-start=\"2499\" data-end=\"2571\"\u003eWhat is the recommended dosage and administration for Roflumilast?\u003c\/h3\u003e\r\n\u003cul data-start=\"2572\" data-end=\"2886\"\u003e\r\n\u003cli data-start=\"2572\" data-end=\"2647\"\u003e\n\u003cstrong data-start=\"2574\" data-end=\"2585\"\u003eDosage:\u003c\/strong\u003e The typical recommended oral dose is \u003cstrong data-start=\"2623\" data-end=\"2644\"\u003e500 µg once daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003cli data-start=\"2648\" data-end=\"2886\"\u003e\n\u003cstrong data-start=\"2650\" data-end=\"2669\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2674\" data-end=\"2886\"\u003e\r\n\u003cli data-start=\"2674\" data-end=\"2777\"\u003eRoflumilast should be taken once daily, with or without food, preferably at the same time each day.\u003c\/li\u003e\r\n\u003cli data-start=\"2780\" data-end=\"2886\"\u003eConsistent use is key to maintaining its anti‑inflammatory effect and improving lung function over time.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2888\" data-end=\"2965\"\u003e\u003cem data-start=\"2888\" data-end=\"2965\"\u003eReference: U.S. FDA Roflumilast Prescribing Information; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2967\" data-end=\"2970\"\u003e\r\n\u003ch3 data-start=\"2972\" data-end=\"3036\"\u003eWhat prescribing information is important for Roflumilast?\u003c\/h3\u003e\r\n\u003cul data-start=\"3037\" data-end=\"3730\"\u003e\r\n\u003cli data-start=\"3037\" data-end=\"3197\"\u003e\n\u003cstrong data-start=\"3039\" data-end=\"3055\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3060\" data-end=\"3197\"\u003e\r\n\u003cli data-start=\"3060\" data-end=\"3197\"\u003eRoflumilast is indicated for reducing the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3198\" data-end=\"3408\"\u003e\n\u003cstrong data-start=\"3200\" data-end=\"3222\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3227\" data-end=\"3408\"\u003e\r\n\u003cli data-start=\"3227\" data-end=\"3294\"\u003eKnown hypersensitivity to roflumilast or any of its components.\u003c\/li\u003e\r\n\u003cli data-start=\"3297\" data-end=\"3408\"\u003eNot recommended for use in patients with moderate to severe liver impairment without careful consideration.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3409\" data-end=\"3539\"\u003e\n\u003cstrong data-start=\"3411\" data-end=\"3426\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3431\" data-end=\"3539\"\u003e\r\n\u003cli data-start=\"3431\" data-end=\"3539\"\u003ePatients should have periodic liver function tests and assessments for potential psychiatric side effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3540\" data-end=\"3730\"\u003e\n\u003cstrong data-start=\"3542\" data-end=\"3569\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3574\" data-end=\"3730\"\u003e\r\n\u003cli data-start=\"3574\" data-end=\"3653\"\u003eRoflumilast should be used as part of a comprehensive COPD management plan.\u003c\/li\u003e\r\n\u003cli data-start=\"3656\" data-end=\"3730\"\u003eThe drug is not intended for the immediate relief of acute bronchospasm.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3732\" data-end=\"3806\"\u003e\u003cem data-start=\"3732\" data-end=\"3806\"\u003eReference: U.S. FDA; WHO; National Institutes of Health (NIH) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3808\" data-end=\"3811\"\u003e\r\n\u003ch3 data-start=\"3813\" data-end=\"3899\"\u003eWhat safety information, warnings, and cautions are associated with Roflumilast?\u003c\/h3\u003e\r\n\u003cul data-start=\"3900\" data-end=\"4672\"\u003e\r\n\u003cli data-start=\"3900\" data-end=\"3987\"\u003e\n\u003cstrong data-start=\"3902\" data-end=\"3926\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3931\" data-end=\"3987\"\u003e\r\n\u003cli data-start=\"3931\" data-end=\"3987\"\u003eDiarrhea, weight loss, nausea, headache, and insomnia.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3988\" data-end=\"4672\"\u003e\n\u003cstrong data-start=\"3990\" data-end=\"4014\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4019\" data-end=\"4672\"\u003e\r\n\u003cli data-start=\"4019\" data-end=\"4180\"\u003e\n\u003cstrong data-start=\"4021\" data-end=\"4045\"\u003ePsychiatric Effects:\u003c\/strong\u003e Roflumilast may be associated with mood changes, anxiety, or depression in some patients. Monitor for signs of psychiatric distress.\u003c\/li\u003e\r\n\u003cli data-start=\"4183\" data-end=\"4323\"\u003e\n\u003cstrong data-start=\"4185\" data-end=\"4214\"\u003eGastrointestinal Effects:\u003c\/strong\u003e Diarrhea and weight loss can occur; patients should be advised to maintain proper hydration and nutrition.\u003c\/li\u003e\r\n\u003cli data-start=\"4326\" data-end=\"4501\"\u003e\n\u003cstrong data-start=\"4328\" data-end=\"4349\"\u003eHepatic Function:\u003c\/strong\u003e There is a risk of liver enzyme elevation; liver function should be monitored periodically, especially in patients with preexisting liver conditions.\u003c\/li\u003e\r\n\u003cli data-start=\"4504\" data-end=\"4672\"\u003e\n\u003cstrong data-start=\"4506\" data-end=\"4541\"\u003eContraindications in Pregnancy:\u003c\/strong\u003e Roflumilast is contraindicated during pregnancy and lactation. Women of childbearing potential should use effective contraception.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4674\" data-end=\"4774\"\u003e\u003cem data-start=\"4674\" data-end=\"4774\"\u003eReference: U.S. FDA Roflumilast Prescribing Information; PubMed literature on PDE4 inhibitors; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4776\" data-end=\"4779\"\u003e\r\n\u003ch3 data-start=\"4781\" data-end=\"4848\"\u003eWhat drug interactions should be considered with Roflumilast?\u003c\/h3\u003e\r\n\u003cul data-start=\"4849\" data-end=\"5364\"\u003e\r\n\u003cli data-start=\"4849\" data-end=\"5067\"\u003e\n\u003cstrong data-start=\"4851\" data-end=\"4873\"\u003eCYP3A4 Inhibitors:\u003c\/strong\u003e\r\n\u003cul data-start=\"4878\" data-end=\"5067\"\u003e\r\n\u003cli data-start=\"4878\" data-end=\"5067\"\u003eConcomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase plasma levels of roflumilast and its active metabolite, potentially enhancing adverse effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5068\" data-end=\"5222\"\u003e\n\u003cstrong data-start=\"5070\" data-end=\"5122\"\u003eOther Medications with Gastrointestinal Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"5127\" data-end=\"5222\"\u003e\r\n\u003cli data-start=\"5127\" data-end=\"5222\"\u003eDrugs that cause gastrointestinal upset may have additive effects when used with roflumilast.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5223\" data-end=\"5364\"\u003e\n\u003cstrong data-start=\"5225\" data-end=\"5248\"\u003eHepatotoxic Agents:\u003c\/strong\u003e\r\n\u003cul data-start=\"5253\" data-end=\"5364\"\u003e\r\n\u003cli data-start=\"5253\" data-end=\"5364\"\u003eCaution is advised when roflumilast is used in patients receiving medications that can impair liver function.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5366\" data-end=\"5428\"\u003e\u003cem data-start=\"5366\" data-end=\"5428\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5430\" data-end=\"5433\"\u003e\r\n\u003ch3 data-start=\"5435\" data-end=\"5530\"\u003eWhere can I find additional clinical evidence and detailed information about Roflumilast?\u003c\/h3\u003e\r\n\u003cp data-start=\"5531\" data-end=\"5621\"\u003eFor further details on clinical studies, dosing, and safety monitoring, please refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5622\" data-end=\"5930\"\u003e\r\n\u003cli data-start=\"5622\" data-end=\"5710\"\u003e\n\u003cstrong data-start=\"5624\" data-end=\"5676\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5677\" data-end=\"5708\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"5711\" data-end=\"5789\"\u003e\n\u003cstrong data-start=\"5713\" data-end=\"5736\"\u003eClinicalTrials.gov:\u003c\/strong\u003e Search for roflumilast studies (e.g., NCT00910696)\u003c\/li\u003e\r\n\u003cli data-start=\"5790\" data-end=\"5857\"\u003e\n\u003cstrong data-start=\"5792\" data-end=\"5828\"\u003eWorld Health Organization (WHO):\u003c\/strong\u003e COPD management guidelines\u003c\/li\u003e\r\n\u003cli data-start=\"5858\" data-end=\"5930\"\u003e\n\u003cstrong data-start=\"5860\" data-end=\"5871\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed research articles on roflumilast in COPD\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5932\" data-end=\"5966\"\u003e\u003cem data-start=\"5932\" data-end=\"5966\"\u003eReference: U.S. FDA; WHO; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5968\" data-end=\"5971\"\u003e\r\n\u003ch3 data-start=\"5973\" data-end=\"5993\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"5994\" data-end=\"6605\"\u003e\u003cstrong data-start=\"5994\" data-end=\"6009\"\u003eRoflumilast\u003c\/strong\u003e is an effective oral PDE4 inhibitor used to reduce the frequency of COPD exacerbations in patients with severe COPD and chronic bronchitis. By increasing cAMP levels in inflammatory cells, it diminishes airway inflammation and improves lung function. Due to its potential gastrointestinal and psychiatric side effects—and its interactions with certain CYP3A4 inhibitors—roflumilast should be prescribed with careful patient selection and monitoring. Always consult your healthcare provider to determine if roflumilast is the appropriate treatment as part of a comprehensive COPD management plan.\u003c\/p\u003e\r\n\u003cp data-start=\"6607\" data-end=\"6831\"\u003e\u003cem data-start=\"6607\" data-end=\"6831\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"500mcg","offer_id":51735706403099,"sku":"Generic-Deliresp-(Roflumilast)-Rofum-1-1","price":35.4,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/rofaday","provider":"EZ Chemist","version":"1.0","type":"link"}